Company profile
Milestone Pharmaceuticals Inc.
NASDAQ: MIST · Healthcare · Biotechnology
Canadian filerHQ Montreal, QCCIK 0001408443Reports USD
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH 48DQ —GM —SS 49
v0.1 · 35/100 weight · pillars only
↑ Piotroski F, market scale · ↓ return on equity, listing tenure
Methodology →Revenue TTM
$2.3M
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$63.1M
Employees
38
as of 2026-08-18
Market cap
$133.2M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$63.1M-$63.1M2025
Operating income-$62.1M-$62.1M2025
Total assets$113.6M$113.6M2025
Liabilities$71.8M$71.8M2025
Equity$41.8M$41.8M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Milestone Pharmaceuticals Inc.’s financial profile?
Milestone Pharmaceuticals Inc. earned -$63.1M in FY2025 net income.
Peers · Healthcare
Canton Strategic Holdings Inc——Indaptus Therapeutics, Inc.——NervGen Pharma Corp. Common stock——Polaryx Therapeutics, Inc. Common Stock——Nautilus Biotechnolgy, Inc.——enGene Holdings Inc.——Key facts
CEOJoseph G. Oliveto
SectorHealthcare
IndustryBiotechnology
HeadquartersMontreal, QC
ExchangeNASDAQ: MIST
Employees38
IPO date2019-05-09
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.